Angelini Pharma Reportedly Explores A Potential Acquisition of Catalyst Pharmaceuticals

Published: 2026-04-27 16:50:33 ET CPRX

Published on 04/27/2026 at 04:50 pm EDT

Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) surged nearly 20% on April 27, 2026, after a report that Italy-based Angelini Pharma S.p.a. is exploring a potential acquisition of the company. The sharp move reflects renewed investor enthusiasm around merger-and-acquisition activity in the biotech sector, where mid-cap specialty drugmakers like Catalyst often become attractive targets for larger or privately held pharmaceutical groups seeking growth. According to a Bloomberg report citing sources familiar with the matter, Angelini Pharma is working with financial advisers as it evaluates a possible bid for Catalyst, which currently carries a market capitalization of $3.3 billion.

While the discussions are said to be in early stages, the mere possibility of a deal was enough to trigger a strong rally in Catalyst?s shares, underscoring how sensitive biotech valuations are to takeover speculation. Angelini Pharma, part of the privately held Angelini Industries group, has been increasingly vocal about its ambitions to expand beyond its core European markets. In a statement, a company representative emphasized that evaluating growth opportunities?including acquisitions?is a central component of its long-term strategy.

However, the company stopped short of confirming any specific interest in Catalyst, noting that there is no guarantee ongoing evaluations will lead to a transaction. Still, several uncertainties remain. Angelini is reportedly reviewing multiple acquisition targets, meaning Catalyst is not the only option on the table.

Additionally, valuation considerations, regulatory hurdles, and strategic fit will all play critical roles in determining whether talks progress.